Open AccessAntimicrobial peptide LL-37 is bactericidal against Staphylococcus aureus biofilms
Author(s) -
Jason Kang,
Matthew J. Dietz,
Bingyun Li
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0216676
Subject(s) - antimicrobial , staphylococcus aureus , microbiology and biotechnology , biofilm , antibiotics , gentamicin , staphylococcal infections , methicillin resistant staphylococcus aureus , biology , chemistry , bacteria , genetics
Our current challenge in the management of prosthetic joint infection is the eradication of biofilms which has driven the need for improved antimicrobial agents and regimens. In this study, the antimicrobial peptide, LL-37, and silver nanoparticles (AgNPs) were investigated for their antimicrobial efficacies against Staphylococcus aureus ( S . aureus ), a microorganism commonly implicated in biofilm-related infections. These antimicrobials were compared to conventional antibiotics and combination treatments with rifampin. Using a Centers for Disease Control reactor, 24 h S . aureus biofilms were formed on cobalt-chromium discs and the anti-biofilm activity was determined by quantifying the amount of colony forming units following treatments. We found that LL-37 was the most efficacious antimicrobial agent with a more than 4 log reduction in colony counts. In comparison, silver nanoparticles and conventional antibiotics were not as efficacious, with a less than 1 log reduction in colony counts. Antimicrobial combination treatments with rifampin significantly increased the log reduction for AgNPs and gentamicin, although still significantly less than LL-37 in isolation. Furthermore, kinetic studies revealed the rapid elimination of S . aureus biofilm with LL-37. Collectively, the results of this study demonstrated that LL-37 was an effective agent against S . aureus biofilms and may have potential clinical applications in the eradication of biofilms and treatment of prosthetic joint infection.